Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Survival outcomes for patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with lutetium-177-dotatate (Lu-177) in a Brazilian reference center: A six-year follow-up experience.
Presenter
Zenaide Silva Souza
Hospital Sírio-Libanês
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 642)
DOI
10.1200/JCO.2023.41.4_suppl.642
Abstract #
642
Poster Bd #
G11
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.
Speaker: Jonathan R. Strosberg, MD
Speaker: Katy K. Tsai, MD
Videos & Slides
2024 ASCO Annual Meeting
Long-term survival outcomes for hormonal therapy in premenopausal patients with clinical stage I endometrial cancer.
Speaker: Yukio Suzuki, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma.
Speaker: Mehdi Touat, MD